Table 2.
Univariate Cox Regression Analyses Results for Disease Progression
| Hazard Ratio (HR) (95% CI) | p Value | |
|---|---|---|
| Age | 0.98 (0.96–1.00) | 0.099 |
| Gender | ||
| Men | 1.00* | |
| Women | 0.48 (0.24–0.96) | 0.039 |
| Smoking | ||
| No | 1.00* | |
| Yes | 1.18 (0.60–2.31) | 0.627 |
| Pack/years | 1.01 (1.00–1.02) | 0.023 |
| Comorbidity | ||
| No | 1.00* | |
| Yes | 1.44 (0.67–3.07) | 0.347 |
| Histological type | ||
| NOS | 1.00* | |
| Adenocarcinoma | 0.72 (0.23–2.30) | 0.580 |
| Squamous cell carcinoma | 0.69 (0.24–1.94) | 0.477 |
| Differentiation (n = 44) | ||
| Low | 1.00* | |
| Moderate | 0.70 (0.31–1.61) | 0.402 |
| EGFR (n = 34) | ||
| Negative | 1.00* | |
| Positive | 0.22 (0.08–0.61) | 0.004 |
| Performance status | ||
| 0–1 | 1.00* | |
| ≥2 | 2.09 (1.17–3.74) | 0.013 |
| Stage | ||
| IIIB | 1.00* | |
| IV | 2.51 (0.78–8.09) | 0.124 |
| Duration of treatment with erlotinib (days) | 0.76 (0.67–0.86) | <0.001 |
| Treatment line | ||
| First | 1.00* | |
| Second | 1.96 (0.98–3.94) | 0.059 |
| Third–fourth | 1.50 (0.68–3.29) | 0.314 |
| Rash | ||
| No | 1.00* | |
| Yes | 0.32 (0.17–0.57) | <0.001 |
| Rash grade | ||
| I | 1.00* | |
| II/III | 1.05 (0.4–2.76) | 0.923 |
| Time to rash (days) | 1.00 (0.99–1.01) | 0.583 |
*
Reference category.